Catequentinib hydrochloride is under clinical development by Advenchen Laboratories and currently in Phase II for Non-Small Cell Lung Cancer.

Envafolimab is under clinical development by Alphamab Oncology and currently in Phase I for Non-Small Cell Lung Cancer.

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

Lung cancer prognosis tends to be better for people diagnosed in earlier stages of the disease. Once you have received a diagnosis and the type of cancer has been identified, your healthcare provider ...

Imfinzi reduced risk of death by 27% and reduced disease progression by 24% compared to patients receiving a placebo. 2. In ...

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 ... Scientists Discover That ...

There are two main types of lung cancer: non-small cell lung ... cancer can spread to any part of the body, but the most common areas include the brain, bones, adrenal glands, liver, and lymph ...

The FDA has approved the drug durvalumab for adults with limited-stage small-cell ... cancer cells more effectively. Imfinzi was first approved by the FDA in 2017 for use against various lung ...

Lung cancer in young adults is often diagnosed later (more likely to be stage IV non-small cell lung cancer at diagnosis) than it is in older adults. This may lead to more symptoms related to the ...